Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00GLQ
|
||||
| Former ID |
DIB001622
|
||||
| Drug Name |
2LM20-4
|
||||
| Synonyms |
Anti-CD20 SMIP (autoimmune disease), Pfizer; Anti-CD20 small modular immunopharmaceutical (autoimmune disease), Pfizer
|
||||
| Indication | Autoimmune diabetes [ICD10:E08-E13] | Investigative | [1] | ||
| Company |
Pfizer Inc
|
||||
| Target and Pathway | |||||
| Target(s) | B-lymphocyte antigen CD20 | Target Info | Modulator | [1] | |
| KEGG Pathway | Hematopoietic cell lineage | ||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.